{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:15:27Z","timestamp":1778598927477,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"DOI":"10.7759\/cureus.108722","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:48:31Z","timestamp":1778597311000},"source":"Crossref","is-referenced-by-count":0,"title":["Molecular Stability as a Translational Gate: A Structured Framework for Target Validation in Genetic Cardiomyopathy"],"prefix":"10.7759","author":[{"given":"Sanghati","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.03.004","article-title":"Global burden of hypertrophic\u00a0cardiomyopathy","volume":"6","author":"Maron BJ","year":"2018","unstructured":"Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic\u00a0cardiomyopathy. JACC Heart Fail. 2018, 6:376-8. 10.1016\/j.jchf.2018.03.004","journal-title":"JACC Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper AR","year":"2021","unstructured":"Harper AR, Goel A, Grace C, et al.. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021, 53:135-42. 10.1038\/s41588-020-00764-0","journal-title":"Nat Genet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.223834","article-title":"Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history","volume":"108","author":"Seidman CE","year":"2011","unstructured":"Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res. 2011, 108:743-50. 10.1161\/CIRCRESAHA.110.223834","journal-title":"Circ Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman DS","year":"2012","unstructured":"Herman DS, Lam L, Taylor MR, et al.. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012, 366:619-28. 10.1056\/NEJMoa1110186","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto I","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al.. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020, 396:759-79. 10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum MJ","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, et al.. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018, 46:D1062-7. 10.1093\/nar\/gkx1153","journal-title":"Nucleic Acids Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.65.092101.142243","article-title":"Cardiac hypertrophy: the good, the bad, and the ugly","volume":"65","author":"Frey N","year":"2003","unstructured":"Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003, 65:45-79. 10.1146\/annurev.physiol.65.092101.142243","journal-title":"Annu Rev Physiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cells15030304","article-title":"Artificial intelligence for exosomal biomarker discovery for cardiovascular diseases: multi-omics integration, reproducibility, and translational prospects","volume":"15","author":"Dinc R","year":"2026","unstructured":"Dinc R, Ardic N. Artificial intelligence for exosomal biomarker discovery for cardiovascular diseases: multi-omics integration, reproducibility, and translational prospects. Cells. 2026, 15:304. 10.3390\/cells15030304","journal-title":"Cells"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2011.01.014","article-title":"Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities","volume":"50","author":"Schlossarek S","year":"2011","unstructured":"Schlossarek S, Mearini G, Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2011, 50:613-20. 10.1016\/j.yjmcc.2011.01.014","journal-title":"J Mol Cell Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2014.02.011","article-title":"Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases","volume":"106","author":"Spudich JA","year":"2014","unstructured":"Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014, 106:1236-49. 10.1016\/j.bpj.2014.02.011","journal-title":"Biophys J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.01.021","article-title":"Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs","volume":"63","author":"Molkentin JD","year":"2004","unstructured":"Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004, 63:467-75. 10.1016\/j.cardiores.2004.01.021","journal-title":"Cardiovasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho CY","year":"2010","unstructured":"Ho CY, L\u00f3pez B, Coelho-Filho OR, et al.. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010, 363:552-63. 10.1056\/NEJMoa1002659","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmccpl.2025.100290","article-title":"Innovations in heart failure management: the role of cutting-edge biomarkers and multi-omics integration","volume":"11","author":"Bastos JM","year":"2025","unstructured":"Bastos JM, Cola\u00e7o B, Baptista R, Gavina C, Vitorino R. Innovations in heart failure management: the role of cutting-edge biomarkers and multi-omics integration. J Mol Cell Cardiol Plus. 2025, 11:100290. 10.1016\/j.jmccpl.2025.100290","journal-title":"J Mol Cell Cardiol Plus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel","volume":"115","author":"Januzzi JL","year":"2015","unstructured":"Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015, 115:26B-31B. 10.1016\/j.amjcard.2015.01.037","journal-title":"Am J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62862","article-title":"Genetic mutations and mechanisms in dilated cardiomyopathy","volume":"123","author":"McNally EM","year":"2013","unstructured":"McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013, 123:19-26. 10.1172\/JCI62862","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel AS","year":"2002","unstructured":"Maisel AS, Krishnaswamy P, Nowak RM, et al.. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002, 347:161-7. 10.1056\/NEJMoa020233","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.300558","article-title":"Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes","volume":"114","author":"Yang X","year":"2014","unstructured":"Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014, 114:511-23. 10.1161\/CIRCRESAHA.114.300558","journal-title":"Circ Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.02.011","article-title":"Organs-on-a-chip: a fast track for engineered human tissues in drug development","volume":"22","author":"Ronaldson-Bouchard K","year":"2018","unstructured":"Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018, 22:310-24. 10.1016\/j.stem.2018.02.011","journal-title":"Cell Stem Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","year":"2020","unstructured":"The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020, 369.1318-30. 10.1126\/science.aaz1776","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk GD","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021, 128:1487-513. 10.1161\/CIRCRESAHA.121.318241","journal-title":"Circ Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e3283375698","article-title":"Genetics of hypertrophic cardiomyopathy","volume":"25","author":"Konno T","year":"2010","unstructured":"Konno T, Chang S, Seidman JG, Seidman CE. Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol. 2010, 25:205-9. 10.1097\/HCO.0b013e3283375698","journal-title":"Curr Opin Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2693","article-title":"RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing","volume":"18","author":"Guo W","year":"2012","unstructured":"Guo W, Schafer S, Greaser ML, et al.. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med. 2012, 18:766-73. 10.1038\/nm.2693","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36154","article-title":"MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice","volume":"119","author":"Callis TE","year":"2009","unstructured":"Callis TE, Pandya K, Seok HY, et al.. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009, 119:2772-86. 10.1172\/JCI36154","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.37349\/emed.2025.1001340","article-title":"AI-driven drug discovery and repurposing using multi-omics for myocardial infarction and heart failure","volume":"6","author":"Sabry Z","year":"2025","unstructured":"Sabry Z, Arora HS, Chandrasekaran S, Wang Z. AI-driven drug discovery and repurposing using multi-omics for myocardial infarction and heart failure. Explor Med. 2025, 6:1001340. 10.37349\/emed.2025.1001340","journal-title":"Explor Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110798","article-title":"Epigallocatechin gallate as a molecular therapeutic in heart failure and cardio-oncology: mechanistic pathways and translational perspectives","volume":"26","author":"Ajaz F","year":"2025","unstructured":"Ajaz F, Haddad J, Huda B, Yousuf M, Patnaik R, Bhurka F, Banerjee Y. Epigallocatechin gallate as a molecular therapeutic in heart failure and cardio-oncology: mechanistic pathways and translational perspectives. Int J Mol Sci. 2025, 26:10798. 10.3390\/ijms262110798","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.242974","article-title":"Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy","volume":"109","author":"Ashrafian H","year":"2011","unstructured":"Ashrafian H, McKenna WJ, Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res. 2011, 109:86-96. 10.1161\/CIRCRESAHA.111.242974","journal-title":"Circ Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.02.015","article-title":"Effectiveness of mobile health technology interventions for\u00a0patients with heart failure: systematic review and meta-analysis","volume":"37","author":"Kitsiou S","year":"2021","unstructured":"Kitsiou S, Vatani H, Par\u00e9 G, et al.. Effectiveness of mobile health technology interventions for\u00a0patients with heart failure: systematic review and meta-analysis. Can J Cardiol. 2021, 37:1248-59. 10.1016\/j.cjca.2021.02.015","journal-title":"Can J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma H","year":"2017","unstructured":"Ma H, Marti-Gutierrez N, Park SW, et al.. Correction of a pathogenic gene mutation in human embryos. Nature. 2017, 548:413-9. 10.1038\/nature23305","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71601","article-title":"Investigating the replicability of preclinical cancer biology","volume":"10","author":"Errington TM","year":"2021","unstructured":"Errington TM, Mathur M, Soderberg CK, Denis A, Perfito N, Iorns E, Nosek BA. Investigating the replicability of preclinical cancer biology. Elife. 2021, 10:10.7554\/eLife.71601","journal-title":"Elife"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.03.006","article-title":"Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy","volume":"4","author":"Wilde AA","year":"2018","unstructured":"Wilde AA, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol. 2018, 4:569-79. 10.1016\/j.jacep.2018.03.006","journal-title":"JACC Clin Electrophysiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.173","article-title":"Pathophysiology of arrhythmogenic cardiomyopathy","volume":"9","author":"Basso C","year":"2011","unstructured":"Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol. 2011, 9:223-33. 10.1038\/nrcardio.2011.173","journal-title":"Nat Rev Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan Y","year":"2025","unstructured":"Yan Y, Liu S, Wen J, et al.. Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications. Mol Cancer. 2025, 24:251. 10.1186\/s12943-025-02463-y","journal-title":"Mol Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cells15080698","article-title":"Transcriptome analysis identifies proteostasis and cell survival pathway disruption in peripartum cardiomyopathy, leading to heart failure","volume":"15","author":"Choubey P","year":"2026","unstructured":"Choubey P, Montoya-Uribe V, Matter ML. Transcriptome analysis identifies proteostasis and cell survival pathway disruption in peripartum cardiomyopathy, leading to heart failure. Cells. 2026, 15:698. 10.3390\/cells15080698","journal-title":"Cells"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1793532","article-title":"AI-driven identification of nutrition-modulated biomarkers and drug targets for cardiovascular therapeutic mechanisms","volume":"17","author":"Luo Y","year":"2026","unstructured":"Luo Y, Mou Y, Li Z, Liao B, Wan J. AI-driven identification of nutrition-modulated biomarkers and drug targets for cardiovascular therapeutic mechanisms. Front Pharmacol. 2026, 17:1793532. 10.3389\/fphar.2026.1793532","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484343-molecular-stability-as-a-translational-gate-a-structured-framework-for-target-validation-in-genetic-cardiomyopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:48:32Z","timestamp":1778597312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484343-molecular-stability-as-a-translational-gate-a-structured-framework-for-target-validation-in-genetic-cardiomyopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.108722","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}